GlassScriptPhysician profile
Marwa Hazzah
NPI 1891956876
$1,202.15
in general payments reported to CMS, 2019-2025
27 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $274 · 2021: $54.76 · 2022: $24.90 · 2023: $66.95 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $391.70 | 2019-2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.46 | 2019-2025 | Jardiance |
| Medtronic, INC. | $99.99 | 2021-2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $55.43 | 2019-2020 | |
| Radius Health, INC. | $53.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $42.34 | 2019 | |
| Corcept Therapeutics | $42.14 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $39.53 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $34.49 | 2019-2025 | |
| Amarin Pharma, INC. | $28.24 | 2019 | |
| Lilly USA, LLC | $27.46 | 2020-2021 | |
| Shire North American Group INC | $26.48 | 2019 | |
| Allergan, INC. | $25.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2019 | |
| Pfizer INC. | $14.82 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Embecta Corp. | $14.77 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Xeris Pharmaceuticals, INC. | $14.70 | 2020 | |
| Novo Nordisk INC | $14.66 | 2019 | |
| Abbott Laboratories | $14.55 | 2019 | |
| Indivior INC. | $14.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.17 | 2019 | |
| Alkermes, INC. | $13.96 | 2019 | |
| Circassia INC. | $13.80 | 2019 | |
| Gilead Sciences, INC. | $13.75 | 2019 | |
| Ibsa Pharma INC. | $13.21 | 2023 | Tirosint, Licart |
| Abbvie INC. | $12.40 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwa Hazzah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.